Analysts' ratings for Evolent Health (NYSE:EVH) over the last quarter vary from bullish to bearish, as provided by 4 analysts.

In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.

	Bullish	Somewhat Bullish	Indifferent	Somewhat Bearish	Bearish
Total Ratings	3	1	0	0	0
Last 30D	1	0	0	0	0
1M Ago	1	0	0	0	0
2M Ago	1	1	0	0	0
3M Ago	0	0	0	0	0

Analysts have set 12-month price targets for Evolent Health, revealing an average target of $8.5, a high estimate of $10.00, and a low estimate of $6.00. This current average represents a 26.85% decrease from the previous average price target of $11.62.

Interpreting Analyst Ratings: A Closer Look

The standing of Evolent Health among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst	Analyst Firm	Action Taken	Rating	Current Price Target	Prior Price Target
David Larsen	BTIG	Lowers	Buy	$8.00	$10.00
David Larsen	BTIG	Lowers	Buy	$10.00	$16.00
Daniel Grosslight	Citigroup	Lowers	Buy	$6.00	$9.50
Constantine Davides	Citizens	Lowers	Market Outperform	$10.00	$11.00

Key Insights:

• Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Evolent Health. This offers insight into analysts' perspectives on the current state of the company.
• Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Evolent Health compared to the broader market.
• Price Targets: Gaining insights, analysts provide estimates for the future value of Evolent Health's stock. This comparison reveals trends in analysts' expectations over time.

Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Evolent Health's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.

Stay up to date on Evolent Health analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Discovering Evolent Health: A Closer Look

Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The primary solutions provided by the company include specialty care management services, total cost of care management, and administrative services.

Financial Insights: Evolent Health

Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.

Negative Revenue Trend: Examining Evolent Health's financials over 3M reveals challenges. As of 30 September, 2025, the company experienced a decline of approximately -22.83% in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: Evolent Health's net margin excels beyond industry benchmarks, reaching -5.62%. This signifies efficient cost management and strong financial health.

Return on Equity (ROE): Evolent Health's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -3.1%, the company may face hurdles in generating optimal returns for shareholders.

Return on Assets (ROA): Evolent Health's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -1.1%, the company may encounter challenges in delivering satisfactory returns from its assets.

Debt Management: Evolent Health's debt-to-equity ratio surpasses industry norms, standing at 1.29. This suggests the company carries a substantial amount of debt, posing potential financial challenges.

Understanding the Relevance of Analyst Ratings

Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.

Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.

This article was generated by Benzinga's automated content engine and reviewed by an editor.